Current adjuvants and new perspectives in vaccine formulation. - Wikidata - wikimedia - TriplyDB

Current adjuvants and new perspectives in vaccine formulation.

Current adjuvants and new perspectives in vaccine formulation.

http://www.wikidata.org/entity/Q37909424

about

Vaccines: from empirical development to rational design Carbon nanotubes as vaccine scaffolds Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model Cyclic GMP-AMP displays mucosal adjuvant activity in mice InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles.A vaccine against methamphetamine attenuates its behavioral effects in mice.Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine TAK1 deficiency in dendritic cells inhibits adaptive immunity in SRBC-immunized C57BL/6 mice Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice.Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action.Staphylococcal enterotoxin B-derived haptens promote sensitization Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.Particulate inorganic adjuvants: recent developments and future outlook.Sulfated radix Cyathulae officinalis polysaccharides act as adjuvant via promoting the dendritic cell maturation and suppressing Treg frequency.Montanide ISA 71 VG is Advantageous to Freund's Adjuvant in Immunization Against S. aureus Infection of Mice.Alginate nanoparticles as a promising adjuvant and vaccine delivery system.Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus.Calcium-dependent protein kinases are potential targets for Toxoplasma gondii vaccine.Phosphorylated Radix Cyathulae officinalis Polysaccharides Act as Adjuvant via Promoting Dendritic Cell Maturation.A bioconjugate leveraging xenoreactive antibodies to alleviate cocaine-induced behavior.

P2860

Q21089599-0FA594E2-204B-4642-A94E-F49F85A7D2CE Q28392532-43D18CB2-1075-4667-BC9C-423F529DE651 Q30376350-3BB32520-F047-4A54-A26A-7874ECC7C6C1 Q30425269-A674ACE5-93B4-4706-AC82-6028363831EE Q34180043-0F8BB574-CF04-41F8-B992-AEF09EBA630D Q34309082-C053FFB6-509C-427E-A814-0CFE4E1FB22A Q35108944-B35251B3-5D1B-4751-A6D0-95D5FEB5F1F3 Q35144633-AEFA1171-45AE-419F-8C7E-6C663FFACA19 Q36326918-4D0726CD-C082-4B06-9156-B86818E17C5D Q36586100-57000DA5-E250-4146-A70F-989EF6DC0A14 Q36702887-D526891A-4F2D-49CC-9BD9-F85DFA89340E Q36953911-097803B0-4E2E-41A8-8309-494078DD536E Q36970200-E575684D-FAD1-49B2-9AA0-44554381129E Q37434385-38D8B152-E172-4C68-9E8D-B9FFCA7FCF4E Q37521363-5E94DC6A-FB5C-4256-90B0-2680EB32F523 Q37729593-A6A9AFC4-482E-448A-8CA0-85D1444FB604 Q37981769-E37A398F-8DED-418D-B36F-33B236EDDAC2 Q38153040-7813FC94-1C42-4237-8439-A85BAD34DBD8 Q38209327-3ECB1EF5-62EA-4874-9BD0-CFCD2D78D885 Q38286377-F5056D32-B951-4773-9283-01A86E34416D Q41210990-B712CB2A-4394-4146-86AA-DF4C68AE97D0 Q41479231-90E0C2B8-F061-4B21-9149-F369EB050DC4 Q42238199-C963ADA3-9A84-4ED3-9DA8-8E50724E6556 Q47558629-D63E775E-D9D6-4C4E-A18D-18F85B598463 Q48109140-2733474C-EDB4-4A7E-98DF-24528076FCCA Q51200585-C27396CB-EBBF-4E82-8A2E-19C3D98BB53E Q53579414-F6B3F523-BCE2-44B4-801A-6BBCDFB3DEE6

P2860

Current adjuvants and new perspectives in vaccine formulation.

http://www.wikidata.org/entity/Q37909424

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current adjuvants and new perspectives in vaccine formulation.

@en

Current adjuvants and new perspectives in vaccine formulation.

@nl

type

label

Current adjuvants and new perspectives in vaccine formulation.

@en

Current adjuvants and new perspectives in vaccine formulation.

@nl

prefLabel

Current adjuvants and new perspectives in vaccine formulation.

@en

Current adjuvants and new perspectives in vaccine formulation.

@nl

P1433

Q37909424-23B30C1E-E00A-4183-BA6F-39A93E8F1DAB

P1476

Q37909424-75022CA9-F462-4917-9EE4-089C1A7CDAC2

P2093

Q37909424-02E26CA8-AF7C-41FC-9255-A90D4422A5E8

Q37909424-2692AC0E-0C87-4059-BEF9-05761D1E56B6

Q37909424-B3594174-566F-42DC-967F-3785E0F875EF

Q37909424-B4FB4BBF-E5B8-44A8-A130-8401D6A5AF74

Q37909424-CC834703-3601-4581-A4BA-2FFD1E0A8DA7

P2860

Q37909424-05811AA3-BA1F-4E90-9F27-0B780B4773C0

Q37909424-0A923220-0414-4A83-9395-EE74A92E7A64

Q37909424-0B1848DD-A347-49C7-B6EE-449EDD85B120

Q37909424-0F68AD9F-FCC9-4903-BF03-36F67AEA74B2

Q37909424-201DBFBA-316C-4D63-9AF8-9DFB000E2FC2

Q37909424-34BDAAE8-149B-4F02-8381-C67E64B5E867

Q37909424-3E75A6BA-0289-47AA-AEF4-60E4A41A1DCE

Q37909424-4083F9D8-D1EC-4547-95E5-5D771C018BDB

Q37909424-48822836-60C1-43E6-971A-EE0E2EE00E1B

Q37909424-4B4B9C98-5502-457A-94ED-AEF6B97C0BE0

P304

Q37909424-616B09EA-D5E7-4524-876F-BB35FB15CC77

P31

Q37909424-07AD5753-C384-43F3-BAFD-DC306B45C086

P356

Q37909424-7CFDA904-43FF-45C6-B76F-FD4B5EE85DAF

P433

Q37909424-7B42A4C5-753D-4DC1-A5BC-20E05CDE5A9C

P478

Q37909424-4AB95CA4-693D-4846-BEBB-D3945D134C81

P50

Q37909424-063A66D0-DAA0-4BCD-BC22-62B410339F70

P577

Q37909424-B933B54A-7AC1-4846-9696-FF6AACB16CD1

P5875

Q37909424-7BD6F002-17A5-4B7F-850F-046D14369420

P698

Q37909424-5DA3B7C0-22C2-4374-AC31-2D0E7BF7996F

P356

P1433

Expert Review of Vaccines

P1476

Current adjuvants and new perspectives in vaccine formulation

@en

P2093

Alfonso De Rosa

http://www.w3.org/2001/XMLSchema#string

Baharak Khadang

http://www.w3.org/2001/XMLSchema#string

Elisa Mennitto

http://www.w3.org/2001/XMLSchema#string

Roberto Camerini

http://www.w3.org/2001/XMLSchema#string

Simona Piccirella

http://www.w3.org/2001/XMLSchema#string

P2860

Immune mechanisms of protection: can adjuvants rise to the challenge?

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Thymosin alpha1: a historical overview

The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism

Toll-like receptor control of the adaptive immune responses

How dying cells alert the immune system to danger

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.

P304

1053-1061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.48

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Emanuele Montomoli

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51537633

http://www.w3.org/2001/XMLSchema#string

P698

21806399

http://www.w3.org/2001/XMLSchema#string